Insights into therapy: Tryptophan oxidation and HIV infection

Michael F. Murray

doi:10.1126/scitranslmed.3001082

Insights into therapy: Tryptophan oxidation and HIV infection

Michael F. Murray

Research output: Contribution to journal › Short survey › peer-review

13 Scopus citations

Abstract

New data from Favre and colleagues strengthen the link between activation of the tryptophan oxidation (TOx) pathway-via the indoleamine 2, 3-dioxygenase enzymes IDO1 and IDO2-and chronic infl ammation in progressive HIV disease. It can now be appreciated that a pathogenic TOx activation cycle exists in HIV. TOx regulation is a therapeutic target for other diseases, such as cancer and autoimmune disorders. Here TOx control is examined with an eye to eventual therapeutic intervention in HIV disease.

Original language	English
Pages (from-to)	32ps23
Journal	Science Translational Medicine
Volume	2
Issue number	32
DOIs	https://doi.org/10.1126/scitranslmed.3001082
State	Published - 2010
Externally published	Yes

Access to Document

10.1126/scitranslmed.3001082

Cite this

@article{1a8d5bd2cd4548b39f79efd21d214fec,

title = "Insights into therapy: Tryptophan oxidation and HIV infection",

abstract = "New data from Favre and colleagues strengthen the link between activation of the tryptophan oxidation (TOx) pathway-via the indoleamine 2, 3-dioxygenase enzymes IDO1 and IDO2-and chronic infl ammation in progressive HIV disease. It can now be appreciated that a pathogenic TOx activation cycle exists in HIV. TOx regulation is a therapeutic target for other diseases, such as cancer and autoimmune disorders. Here TOx control is examined with an eye to eventual therapeutic intervention in HIV disease.",

author = "Murray, {Michael F.}",

year = "2010",

doi = "10.1126/scitranslmed.3001082",

language = "English",

volume = "2",

pages = "32ps23",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "32",

}

TY - JOUR

T1 - Insights into therapy

T2 - Tryptophan oxidation and HIV infection

AU - Murray, Michael F.

PY - 2010

Y1 - 2010

N2 - New data from Favre and colleagues strengthen the link between activation of the tryptophan oxidation (TOx) pathway-via the indoleamine 2, 3-dioxygenase enzymes IDO1 and IDO2-and chronic infl ammation in progressive HIV disease. It can now be appreciated that a pathogenic TOx activation cycle exists in HIV. TOx regulation is a therapeutic target for other diseases, such as cancer and autoimmune disorders. Here TOx control is examined with an eye to eventual therapeutic intervention in HIV disease.

AB - New data from Favre and colleagues strengthen the link between activation of the tryptophan oxidation (TOx) pathway-via the indoleamine 2, 3-dioxygenase enzymes IDO1 and IDO2-and chronic infl ammation in progressive HIV disease. It can now be appreciated that a pathogenic TOx activation cycle exists in HIV. TOx regulation is a therapeutic target for other diseases, such as cancer and autoimmune disorders. Here TOx control is examined with an eye to eventual therapeutic intervention in HIV disease.

UR - http://www.scopus.com/inward/record.url?scp=77952968839&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3001082

DO - 10.1126/scitranslmed.3001082

M3 - Short survey

C2 - 20484729

AN - SCOPUS:77952968839

SN - 1946-6234

VL - 2

SP - 32ps23

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 32

ER -

Insights into therapy: Tryptophan oxidation and HIV infection

Abstract

Access to Document

Fingerprint

Cite this